Home/Pipeline/Cancer Against Itself Platform

Cancer Against Itself Platform

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Earli

About Earli

Earli is a private, pre-clinical stage biotech founded in 2018, pioneering a novel approach to cancer treatment and detection. Its core technology uses AI to design genetic switches delivered via proprietary lipid nanoparticles (cancerLNPs) that activate only in cancer cells, programming them to produce immune-stimulating therapies locally within the tumor. This 'Cancer Against Itself' strategy aims to enhance the efficacy and safety of immuno-oncology by avoiding systemic toxicity. The company has garnered significant attention, substantial venture funding, and recognition from initiatives like the White House Cancer Moonshot.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed